CN102421767B - 苯并呋喃衍生物 - Google Patents

苯并呋喃衍生物 Download PDF

Info

Publication number
CN102421767B
CN102421767B CN201080020315.2A CN201080020315A CN102421767B CN 102421767 B CN102421767 B CN 102421767B CN 201080020315 A CN201080020315 A CN 201080020315A CN 102421767 B CN102421767 B CN 102421767B
Authority
CN
China
Prior art keywords
compound
group
alkyl
reaction
moles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080020315.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102421767A (zh
Inventor
塚本彻哉
若林健志
邑乐泰一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to CN201410213851.4A priority Critical patent/CN103965147B/zh
Publication of CN102421767A publication Critical patent/CN102421767A/zh
Application granted granted Critical
Publication of CN102421767B publication Critical patent/CN102421767B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201080020315.2A 2009-03-10 2010-03-09 苯并呋喃衍生物 Expired - Fee Related CN102421767B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410213851.4A CN103965147B (zh) 2009-03-10 2010-03-09 苯并呋喃衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-056719 2009-03-10
JP2009056719 2009-03-10
PCT/JP2010/054286 WO2010104194A1 (en) 2009-03-10 2010-03-09 Benzofuran derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410213851.4A Division CN103965147B (zh) 2009-03-10 2010-03-09 苯并呋喃衍生物

Publications (2)

Publication Number Publication Date
CN102421767A CN102421767A (zh) 2012-04-18
CN102421767B true CN102421767B (zh) 2014-06-18

Family

ID=42224778

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080020315.2A Expired - Fee Related CN102421767B (zh) 2009-03-10 2010-03-09 苯并呋喃衍生物
CN201410213851.4A Expired - Fee Related CN103965147B (zh) 2009-03-10 2010-03-09 苯并呋喃衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410213851.4A Expired - Fee Related CN103965147B (zh) 2009-03-10 2010-03-09 苯并呋喃衍生物

Country Status (37)

Country Link
US (4) US8957069B2 (enExample)
EP (2) EP2406243B1 (enExample)
JP (2) JP5746631B2 (enExample)
KR (1) KR20110128913A (enExample)
CN (2) CN102421767B (enExample)
AR (1) AR076098A1 (enExample)
AU (1) AU2010221979A1 (enExample)
BR (1) BRPI1009252A2 (enExample)
CA (1) CA2754904A1 (enExample)
CL (1) CL2011002206A1 (enExample)
CO (1) CO6420340A2 (enExample)
CR (1) CR20110474A (enExample)
CY (1) CY1115469T1 (enExample)
DK (1) DK2406243T3 (enExample)
DO (1) DOP2011000281A (enExample)
EA (1) EA201171020A1 (enExample)
EC (1) ECSP11011318A (enExample)
ES (1) ES2487616T3 (enExample)
HK (1) HK1202293A1 (enExample)
HR (1) HRP20140687T1 (enExample)
IL (1) IL214667A0 (enExample)
MA (1) MA33159B1 (enExample)
MX (1) MX2011009394A (enExample)
NZ (1) NZ594847A (enExample)
PE (1) PE20120357A1 (enExample)
PL (1) PL2406243T3 (enExample)
PT (1) PT2406243E (enExample)
RS (1) RS53416B (enExample)
SG (1) SG173757A1 (enExample)
SI (1) SI2406243T1 (enExample)
SM (1) SMT201500027B (enExample)
TN (1) TN2011000422A1 (enExample)
TW (1) TWI477497B (enExample)
UA (1) UA107657C2 (enExample)
UY (1) UY32481A (enExample)
WO (1) WO2010104194A1 (enExample)
ZA (1) ZA201106045B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120357A1 (es) * 2009-03-10 2012-05-03 Takeda Pharmaceutical Derivados de benzofurano
WO2011062194A1 (ja) 2009-11-18 2011-05-26 武田薬品工業株式会社 アミノピリジン誘導体
KR102244874B1 (ko) 2012-02-20 2021-04-28 바스프 에스이 중합체를 사용한 살생물제의 항미생물 활성의 증진
US9816233B2 (en) * 2012-09-28 2017-11-14 Kimberly-Clark Worldwide, Inc. Hybrid fiber compositions and uses in containerboard packaging
US9908680B2 (en) 2012-09-28 2018-03-06 Kimberly-Clark Worldwide, Inc. Tree-free fiber compositions and uses in containerboard packaging
MX2015002398A (es) * 2012-10-01 2015-06-05 Hoffmann La Roche Benzimidazoles como agentes activos del sistema nervioso central.
EP3044207B1 (en) * 2013-09-12 2017-10-18 F. Hoffmann-La Roche AG Indol-carboxamide derivatives
JP7221202B2 (ja) 2017-06-23 2023-02-13 協和キリン株式会社 α、β不飽和アミド化合物
CN109580790A (zh) * 2017-09-28 2019-04-05 安徽省庆云医药股份有限公司 一种液相色谱法分离测定西洛多辛及其光学异构体的方法
CN108530405A (zh) * 2018-05-08 2018-09-14 南京晓庄学院 非金属路易斯酸催化烯烃分子内加成c-o键合成苯并呋喃衍生物的方法
CN109879839B (zh) * 2019-03-12 2023-04-25 沈阳大学 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
UY39129A (es) * 2020-03-16 2021-10-29 Novartis Ag Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CN111362965B (zh) * 2020-04-27 2022-05-03 梯尔希（南京）药物研发有限公司 一种莫西菌素杂质的制备方法
CN113219085B (zh) * 2021-03-31 2022-05-13 河北国龙制药有限公司 一种2,3-二甲基溴苯有关物质的检测方法
CN113214205B (zh) * 2021-04-09 2022-06-10 南方海洋科学与工程广东省实验室(湛江) 一种色原酮衍生物的制备方法
CN115260136B (zh) * 2022-08-09 2023-08-15 嘉兴学院 一种苯酞类化合物及其制备方法
CN115724721A (zh) * 2022-12-19 2023-03-03 山东京博石油化工有限公司 一种2-取代基-4-溴苯酚的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333764A (zh) * 1998-12-04 2002-01-30 武田药品工业株式会社 苯并呋喃衍生物及其制备和用途
EP1411052A1 (en) * 2001-07-05 2004-04-21 Takeda Chemical Industries, Ltd. Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof
CN1638763A (zh) * 2002-03-01 2005-07-13 武田药品工业株式会社 抗抑郁剂
CN1997635A (zh) * 2003-10-24 2007-07-11 惠氏公司 作为5ht2c激动剂的二氢苯并呋喃基烷胺衍生物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128993B (en) 1982-10-08 1986-01-15 Ciba Geigy Ag Benzofurans
JPH04149546A (ja) 1990-10-15 1992-05-22 Konica Corp 有機着色物質の光褪色防止方法
IE68675B1 (en) 1990-11-01 1996-07-10 Takeda Chemical Industries Ltd Aminocoumaran derivatives their production and use
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
JPH11514333A (ja) 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
DE19514567A1 (de) 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
CA2262453A1 (en) 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated Modulators of .beta.-amyloid peptide aggregation comprising d-amino acids
JP4149546B2 (ja) 1996-12-24 2008-09-10 株式会社東芝 半導体装置の製造方法
JPH1149765A (ja) * 1997-06-05 1999-02-23 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
EP0988289A2 (en) * 1997-06-05 2000-03-29 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use
CA2297825C (en) 1997-07-25 2006-03-14 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
DE19932314A1 (de) 1999-07-10 2001-01-11 Merck Patent Gmbh Benzofuranderivate
CN1365359A (zh) 1999-07-29 2002-08-21 伊莱利利公司 苯并呋喃哌嗪和苯并呋喃基高哌嗪:血清素激动剂
DE19958496A1 (de) 1999-12-04 2001-06-07 Merck Patent Gmbh Verfahren zur Herstellung von 5-(1-Piperazinyl)-benzofuran-2-carboxamid durch Übergangsmetallkatalysierte Aminierung
US20040094431A1 (en) * 2000-06-12 2004-05-20 Howard A. Fromson Brush graining
CA2424870A1 (en) 2000-10-05 2003-04-04 Takeda Chemical Industries, Ltd. Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells
IL164341A0 (en) 2002-04-02 2005-12-18 Janssen Pharmaceutica Nv Substituted amino isoxazoline derivatives and their use as anti-depressants
EP1350769A1 (de) * 2002-04-04 2003-10-08 Bystronic Maschinen AG Vorrichtung und Verfahren zum Teilen von vertikalen Glasplatten
MXPA05001631A (es) 2002-08-12 2005-08-19 Takeda Pharmaceutical Derivado de benceno fusionado y su uso.
NZ542823A (en) 2003-04-23 2009-03-31 Schering Corp 2-Alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
WO2004113316A1 (en) 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor viia
DE10326939A1 (de) 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DK1637527T3 (da) 2003-06-26 2013-07-01 Takeda Pharmaceutical Cannabinoid receptor modulator.
JP3678733B2 (ja) * 2003-10-03 2005-08-03 株式会社エヌ・ティ・ティ・ドコモ 携帯通信端末及び位置情報提供方法
US20050095401A1 (en) * 2003-11-04 2005-05-05 Fuji Photo Film Co., Ltd. Image recording material and depression-and-protrusion forming method
WO2005095401A1 (en) 2004-03-22 2005-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
ES2342082T3 (es) 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
DE102004063797A1 (de) 2004-12-30 2006-07-13 Schwarz Pharma Ag Sauerstoffhaltige annelierte Phenylpiperazin- und Phenyldiazepancarboxamide
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
PL1874781T3 (pl) * 2006-04-19 2009-12-31 Boehringer Ingelheim Int Dihydrotienopirymidyny do leczenia chorób zapalnych
EP2009005A4 (en) 2006-04-19 2010-06-02 Astellas Pharma Inc AZOLECARBOXAMIDE DERIVATIVE
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
HU230729B1 (hu) 2007-05-30 2017-12-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Új, szelektív 5HT7-receptorgátló benzofurán-származékok és eljárás előállításukra
US8382180B2 (en) * 2007-10-31 2013-02-26 Applied Material, Inc. Advanced FI blade for high temperature extraction
KR101616140B1 (ko) 2008-03-05 2016-04-27 다케다 야쿠힌 고교 가부시키가이샤 복소환 화합물
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
PE20120357A1 (es) 2009-03-10 2012-05-03 Takeda Pharmaceutical Derivados de benzofurano

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333764A (zh) * 1998-12-04 2002-01-30 武田药品工业株式会社 苯并呋喃衍生物及其制备和用途
EP1411052A1 (en) * 2001-07-05 2004-04-21 Takeda Chemical Industries, Ltd. Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof
CN1638763A (zh) * 2002-03-01 2005-07-13 武田药品工业株式会社 抗抑郁剂
CN1997635A (zh) * 2003-10-24 2007-07-11 惠氏公司 作为5ht2c激动剂的二氢苯并呋喃基烷胺衍生物

Also Published As

Publication number Publication date
CN102421767A (zh) 2012-04-18
WO2010104194A1 (en) 2010-09-16
US8957069B2 (en) 2015-02-17
JP2015044848A (ja) 2015-03-12
EP2781513A1 (en) 2014-09-24
UY32481A (es) 2010-09-30
US8288390B2 (en) 2012-10-16
ECSP11011318A (es) 2011-10-31
US20120046277A1 (en) 2012-02-23
PL2406243T3 (pl) 2014-10-31
ZA201106045B (en) 2012-10-31
UA107657C2 (uk) 2015-02-10
US20120232095A1 (en) 2012-09-13
MA33159B1 (fr) 2012-03-01
SI2406243T1 (sl) 2014-08-29
EA201171020A1 (ru) 2012-03-30
DK2406243T3 (da) 2014-07-21
HK1202293A1 (en) 2015-09-25
PT2406243E (pt) 2014-07-11
CL2011002206A1 (es) 2012-02-03
CO6420340A2 (es) 2012-04-16
IL214667A0 (en) 2011-09-27
CN103965147A (zh) 2014-08-06
SMT201500027B (it) 2015-05-05
TN2011000422A1 (en) 2013-03-27
EP2406243B1 (en) 2014-05-07
EP2406243A1 (en) 2012-01-18
US20120232096A1 (en) 2012-09-13
AU2010221979A1 (en) 2011-09-15
TW201036960A (en) 2010-10-16
HRP20140687T1 (hr) 2014-10-24
MX2011009394A (es) 2011-10-11
CN103965147B (zh) 2016-08-24
DOP2011000281A (es) 2011-10-31
JP5746631B2 (ja) 2015-07-08
CA2754904A1 (en) 2010-09-16
CR20110474A (es) 2011-12-01
RS53416B (sr) 2014-12-31
TWI477497B (zh) 2015-03-21
CY1115469T1 (el) 2017-01-04
JP5841651B2 (ja) 2016-01-13
JP2012520238A (ja) 2012-09-06
KR20110128913A (ko) 2011-11-30
AR076098A1 (es) 2011-05-18
SG173757A1 (en) 2011-09-29
PE20120357A1 (es) 2012-05-03
BRPI1009252A2 (pt) 2016-03-15
NZ594847A (en) 2013-10-25
US20100234357A1 (en) 2010-09-16
ES2487616T3 (es) 2014-08-22

Similar Documents

Publication Publication Date Title
CN102421767B (zh) 苯并呋喃衍生物
CN101573357B (zh) 吲哚化合物
CN101094848B (zh) 有机化合物
CN109153643A (zh) 取代的吲哚mcl-1抑制剂
CN101553469A (zh) 羧酸衍生物
TW201706275A (zh) 具有ｈｉｖ複製抑制作用之含氮３環性衍生物
CN103261176B (zh) 1,4-氧杂氮杂环庚烷衍生物
AU2021410119A1 (en) Tetrahydroquinoline derivative and medicinal use thereof
CN102781914A (zh) 吲哚衍生物
JPWO2008007664A1 (ja) 二環性複素環化合物およびその用途
CN106795177A (zh) Bace1抑制剂
WO2006115285A1 (ja) 医薬組成物
WO2023249106A1 (ja) 筋萎縮性側索硬化症の治療剤又は予防剤
HK1233249B (zh) Bace1抑制剂
HK1160860A (en) Benzofuran derivatives
HK1160860B (en) Benzofuran derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140618

Termination date: 20180309